Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shiyi Yang"'
Autor:
Cyrille Hulin, Christoph Heuck, Hartmut Goldschmidt, Lionel Karlin, Lauriane Clement-Filliatre, Shiyi Yang, Albert Oriol, Hila Magen, Mathias Haenel, Helen McCarthy, Paula Rodriguez-Otero, Philippe Moreau, Cyrille Touzeau, Kenshi Suzuki, Ajai Chari, Michele Kosh, Shinsuke Iida, Vladimir Maisnar, Maria Delioukina, Anna Sureda Balari, Luděk Pour, Vania Hungria
Publikováno v:
Blood. 136:28-30
Introduction: DARA is a human IgGκ monoclonal antibody targeting CD38 and is approved for intravenous (IV) infusion across lines of therapy for MM. In phase 3 clinical studies, DARA IV plus Rd for RRMM (POLLUX) and DARA IV plus VMP for transplant-in
Autor:
Denis Caillot, Shiyi Yang, Vincent H.J. van der Velden, Sonja Zweegman, Lionel Karlin, Margaret Macro, Niels W.C.J. van de Donk, Marie C. Béné, Fabio Rigat, Herve Avet Loiseau, Saskia K. Klein, Carla de Boer, Mark-David Levin, Jessica Vermeulen, Jérôme Lambert, Mohamad Mohty, Maria Krevvata, Tobias Kampfenkel, Aurore Perrot, Cyrille Hulin, Annemiek Broyl, Kon-Siong G. Jie, Veronique Vanquickelberghe, Pieter Sonneveld, Michel Delforge, Fritz Offner, Soraya Wuilleme, Jill Corre, Philippe Moreau, Bertrand Arnulf, Anne-Marie Stoppa
Publikováno v:
Blood. 138:82-82
Introduction: The 2-part phase 3 CASSIOPEIA study (NCT02541383) investigated the combination of DARA with VTd (D-VTd) in transplant-eligible NDMM pts. D-VTd induction/consolidation (ind/cons) led to increased rates of MRD negativity and prolonged pro
Autor:
Paula Rodriguez-Otero, Amrita Krishnan, Brandi Hilder, Elham Askari, Xuewen Ma, Shiyi Yang, Ajai Chari, Jenna D. Goldberg, Luciano J. Costa, Maria-Victoria Mateos, Suzette Girgis, Monique C. Minnema, Jesus G. Berdeja, Niels W.C.J. van de Donk, Jeffery S. Russell, Albert Oriol, Raluca Verona
Publikováno v:
Blood. 138:158-158
Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high exp
Autor:
Dolly A. Parasrampuria, Maria Delioukina, Aurore Perrot, Ming Qi, Ludek Pour, Ajai Chari, Kenshi Suzuki, Vania Hungria, Jesús F. San-Miguel, Anna Sureda, Robin Carson, Helen McCarthy, Cyrille Touzeau, Lionel Karlin, Hila Magen, Shinsuke Iida, Michele Kosh, Vladimir Maisnar, Shiyi Yang, Tara Masterson, Cyrille Hulin
Publikováno v:
Blood. 134:3152-3152
Introduction : Daratumumab (DARA) 16 mg/kg intravenous (IV) is approved as monotherapy for relapsed or refractory multiple myeloma (RRMM) and in combination with standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma (ND